Isoniazid is a topic covered in the Washington Manual of Medical Therapeutics.

To view the entire topic, please or purchase a subscription.

The Washington Manual of Medical Therapeutics helps you diagnose and treat hundreds of medical conditions. Consult clinical recommendations from a resource that has been trusted on the wards for 50+ years. Explore these free sample topics:

Washington Manual

-- The first section of this topic is shown below --

General Principles

Isoniazid (INH; 300 mg PO q24h) exerts bactericidal effects by interfering with the synthesis of lipid components of the mycobacterial cell wall. INH is a component of most TB treatment regimens and can be given twice a week in directly observed therapy (15 mg/kg/dose; 900 mg maximum). INH remains the drug of choice for treatment of latent TB infection (300 mg PO q24h for 9 months, or combined with rifapentine in a 12-week regimen).

-- To view the remaining sections of this topic, please or purchase a subscription --